Combining network pharmacology and bioinformatics to identify bioactive compounds and potential mechanisms of action of *Sedum aizoon* L in the treatment of atherosclerosis

**Bo Jie Zhu**1, Guan Ye Nai2, Tian Xiao Pan1, Zhuo Fei Ma3, Wei Jie Zhou4*

1Department of Chinese Medicine, the People’s Hospital of Baise, Baise, China; 2School of Dentistry, The Youjiang Medical University for Nationalities, Baise, China; 3Department of Hematology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China; 4Department of Clinical Laboratory, the People’s Hospital of Baise, Baise, China

*These authors contributed equally to this work.

**Corresponding Authors:** Zhuo Fei Ma, Department of Hematology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China. Email: mazhuofei2021@stu.gxtcmu.edu.cn; Wei Jie Zhou, Department of Clinical Laboratory, the People’s Hospital of Baise, China. Email: 13377261109@ymcn.edu.cn

Received: 1 June 2023; Accepted: 3 July 2023; Published: 31 August 2023

© 2023 Codon Publications

OPEN ACCESS

ORIGINAL ARTICLE

**Abstract**

*Sedum aizoon* L (SL) is a medicinal plant containing several active components with anti-inflammatory, hemostatic, and blood pressure lowering effects. The aim of this research was to investigate the main pathways, mechanisms, and active components of SL to treat atherosclerosis (AS) through network pharmacology. The active ingredients and their targets of action were obtained by setting the active ingredient-screening conditions using SL as a keyword in the Traditional Chinese Medicine (TCM) System Pharmacology Database and Analysis Platform. The differentially expressed genes related to AS were obtained from the Gene Expression Omnibus database, and the targets related to the treatment of AS were retrieved from databases, such as DisGeNet and GENECARDS, and the targets of AS and SL were intersected using the Cytoscape software platform and applied to construct a drug–compound–target–pathway network map. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, and protein–protein interaction were performed to explore the mechanisms of action of SL against AS. In all, 12 active ingredients were screened from the chemical composition of SL, among which myricetin, oleanolic acid, ursolic acid, sitosterol, and beta-sitosterol were the major active ingredients for the anti-atherosclerotic effect of SL. Combining the active ingredient–target network and disease–target protein–protein interaction (PPI) network, GO and KEGG analysis, tumor necrosis factor signaling pathway, and interleukin-17 signaling pathway were the key pathways of action. SL acts as an anti-atherosclerotic agent through multiple chemical components, targets, and pathways. The active ingredients of SL mainly play the role of prevention and treatment of AS by inhibiting inflammatory response, as an antioxidant, and by lowering blood lipids, thereby providing the theoretical basis for its clinical use.

**Keywords:** Sedum aizoon L; atherosclerosis; network pharmacology

**Introduction**

Cardiovascular disease is currently one of the leading causes of human mortality, and atherosclerosis (AS) is the pathophysiological basis and etiology of all cardiovascular diseases (Humphries et al., 2018; Liu et al., 2019; Sun et al., 2018; Troidl et al., 2020; Xi et al., 2021). AS is a slowly developing, complex inflammatory vascular
Network pharmacology and bioinformatics to identify bioactive compounds

In recent years, traditional Chinese medicine and its active ingredients have become a hot spot for anti-AS drug research because of their mild effects, low toxicity, multiple pathways, and multiple targets in the prevention and treatment of AS and related cardiovascular and cerebrovascular diseases (Song et al., 2021). Researchers have now elucidated that andrographolide and berberine may exert their anti-AS effects through nuclear factor kappa B/CCAAT/enhancer-binding protein beta/peroxisome proliferator-activated receptor gamma (NF-kB/CEBPB/PPARG) signaling pathway, and mitogen-activated protein kinase (MAPK) and phosphoinositide-3-kinase–Akt strain transforming (PI3K/Akt) signaling pathway, providing a theoretical basis for the treatment of AS by Chinese medicine (Shi et al., 2022; Xie et al., 2020). Zhang Q et al. Study revealed that phenylpropanoids, flavonoids, terpenoids, and alkaloids via the protection of vascular endothelial cells from oxidative stress Activation of Nrf2/HO-1 signaling (35024180) as well. Other research showed that berberine protected from carotid atherosclerosis via PI3K/AKTmTOR signaling pathway34592881. Sedum aizoon L (SL) is a perennial herb of the genus Sedum belonging to the family Sedum, which contains a large number of saprophytic, phenolic, and flavonoid substances (Wang et al., 2021). Current studies have shown that SL has anti-inflammatory, hemostatic, antibacterial, and blood pressure-lowering effects, in addition to in vitro inhibition of tumor cell proliferation and regulation of oxidative stress in the body (Li et al., 2017; Wang et al., 2021; Xu et al., 2015). Combined with the above findings, it is suggested that SL has a potential anti-AS clinical value and deserves to be explored in depth.

Network pharmacology has become a popular tool for drug research in recent years, and its systematic and holistic features provide new ideas for the study of complex drug systems, which are widely used to screen active ingredients and elucidate mechanisms of action etc. to provide technical support for rational clinical drug use and promote the application and development of drugs, especially in traditional Chinese medicine, where significant results have been achieved (Wu et al., 2018; Zhou et al., 2020). Therefore, in this research, we attempted to elucidate the targets, active ingredients, and possible mechanisms of SL for treating AS.

Method

Active ingredients of Sedum aizoon L

We used the Traditional Chinese Medicine (TCM) System Pharmacology Database (TCMSP) database to search for the main active ingredients of SL and obtain main target genes for the action of the active ingredients. Finally, we used the Cytoscape software platform (version 3.9.0) to visualize main active ingredients and their targets. The shades of color and the size of graphs were used to visualize connection between active ingredients and targets. The shades of color and the size of graphs were determined by the connectivity of active ingredients and target.

Therapeutic targets of atherosclerosis

We searched DisGeNet (repositories of human gene–disease associations; https://www.disgenet.org/) and GENECARDS (human genes and model orthologues; https://www.genecards.org/) databases with the keyword “atherosclerosis.” We searched therapeutic targets for AS using the keyword “atherosclerosis.” Subsequently, AS-related databases were searched from the Gene Expression Omnibus (GEO) database, and GSE28829 and GSE43292 were included. We then normalized the data set using “Limma” (“linear models for microarray data”) package in R language and searched for differentially expressed genes (DEGs); the criteria was fold change of more than 1, with \( P < 0.05 \), and included them in the follow-up study.

SL potential therapeutic targets

We obtained DEGs from the GEO database, and then obtained AS-related targets with DisGeNet and GENECARDS databases, and at least two or three intersections were considered as AS-related therapeutic targets. The AS-related therapeutic targets were then intersected with the therapeutic targets of Jing tian Panax notoginseng (Chinese ginseng), and the intersected
genes were the AS-related targets of Jing tian Panax notoginseng.

**Protein–protein interaction (PPI), Kyoto Encyclopedia of Genes and Genomes, and gene ontology (GO) analysis**

We obtained the target genes associated with Jing tian Panax notoginseng for AS treatment, and to reveal the functions of the target genes, we performed GO annotation and KEGG pathway enrichment analysis using the R package clusterProfiler. GO terms consisted of the following: biological process (BP), cellular component (CC), and molecular function (MF); \( q < 0.05 \) was considered as statistically significant. The target genes were imported into the Search Tool for the Retrieval of Interacting Genes (STRING) database (https://string-db.org/) to construct a functional PPI network. Interaction score > 0.4 was fixed. Finally, we used Cytoscape (version 3.9.0) to visualize main active ingredients and their targets of action, with the shade of color and the size of the graph determined by the connectivity of active ingredients and the targets of action.

**Molecular docking**

First, the active ingredients from core targets of SL for AS treatment were identified. Two-dimensional (2D) structures were retrieved from the PubChem website and converted to the lowest energy 3D structures using ChemBio3D. Then, the 3D structures of core targets were obtained from the Protein Data Bank (PDB) database, and the “PyMOL” software was used to remove water and ligands. Next, we used the “AutoDockTools” software to convert proteins and drug components into Protein Data Bank, Partial Charge (Q), & Atom Type (T) (PDBQT) format files to identify active pockets. Finally, the AutoDock Vina software was used to perform molecular docking. Finally, the “PyMOL” (an open source but proprietary molecular visualization system) software was used to visualize docking results.

**Identification of core active ingredients and their mechanisms of action**

We performed intersection analysis of the therapeutic targets of active ingredients and AS. The most overlapping target genes were considered as core ingredients to treat AS and were included in the subsequent analysis. We continued to construct PPIs using STRING and Cytoscape in the same way as done earlier. Overlapping genes were also subjected to GO and KEGG using the R language to assess their potential mechanism to treat AS.

**Statistical analysis**

Data were mainly obtained by downloading from public databases. Data were considered statistically significant for differential gene identification with a fold change of more than 1, with \( P < 0.05 \), and for GO and KEGG analysis, with \( q < 0.05 \).

**Results**

**Active components and targets of Sedum aizoon L**

According to predetermined criteria, 134 therapeutic targets and 12 active ingredients of SL were acquired from TCMSP, and the regulatory network of active ingredients and targets of SL were constructed by using Cytoscape. As shown in Figure 1, the center circle is the active ingredient of SL, and the surrounding circles are the targets. This shows that the top three active ingredients are ursolic acid, beta-sitosterol, and myricetin (Table 1).

**Target screening of atherosclerosis**

Atherosclerosis-related database was searched by DisGeNet and GENECARDS databases with the keyword “atherosclerosis” to obtain the therapeutic targets of AS. GSE28829 and GSE43292 data sets were obtained. In the GSE28829 dataset, 157 genes were up-regulated and 25 genes were down-regulated. In the GSE43292 dataset, 75 genes were up-regulated and 57 genes were down-regulated (Figure 2).

**Figure 1. Targets and active ingredients of SL.**
Network pharmacology and bioinformatics to identify bioactive compounds

Potential therapeutic targets

While DEGs were screened from the GEO dataset, the AS-related gene intersections from the DisGeNet and GENECARDS databases were screened for targets that intersected at least twice or thrice and defined as AS-related therapeutic targets. Finally, we screened 67 potential targets of SL for treating AS (Figure 3).

GO, KEGG, and PPI network analysis

In order to explore further the mechanism of treating AS, we performed enrichment analysis and PPI network construction for the above screened targets. First, we identified genes that intersected in the two databases. In terms of BP, the targets were mainly enriched in response

Table 1. Active ingredients of SL.

<table>
<thead>
<tr>
<th>MOL ID</th>
<th>Active Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOL002008</td>
<td>Myricetin</td>
</tr>
<tr>
<td>MOL002075</td>
<td>1-{(2S)-1-Methyl-2-piperidyl}acetone</td>
</tr>
<tr>
<td>MOL002083</td>
<td>Oleanolic acid</td>
</tr>
<tr>
<td>MOL002930</td>
<td>Tyrosol</td>
</tr>
<tr>
<td>MOL000357</td>
<td>Sitoglobuside</td>
</tr>
<tr>
<td>MOL000358</td>
<td>Beta-sitosterol</td>
</tr>
<tr>
<td>MOL000359</td>
<td>Sitosterol</td>
</tr>
<tr>
<td>MOL000511</td>
<td>Ursolic acid</td>
</tr>
<tr>
<td>MOL000513</td>
<td>3,4,5-Trihydroxybenzoic acid</td>
</tr>
<tr>
<td>MOL000579</td>
<td>Hydroquinone</td>
</tr>
<tr>
<td>MOL000606</td>
<td>Isomyricitrin</td>
</tr>
<tr>
<td>MOL0006089</td>
<td>(1R)-2-{(2S)-1-Methyl-2-piperidyl}-1-phenyl-ethanol</td>
</tr>
</tbody>
</table>

MOL: molecular.

Figure 2. Therapeutic targets of AS. (A and B) Volcano plot and heat map of GSE28829 dataset. (C and D) Volcano plot and heat map of GSE43292 dataset.
to lipopolysaccharide and response to oxidative stress, mainly focused on membrane raft and membrane microdomain. On MF, mainly endopeptidase activity, RNA polymerase II transcription factor binding and KEGG enrichment analysis showed that the targets were mainly enriched in lipid and AS, AGE-RAGE signaling pathway in diabetic complications, tumor necrosis factor (TNF) signaling pathway in diabetic complications, TNF signaling pathway and interleukin-17 (IL-17) signaling pathway (Figure 4). While seven intersecting genes were present in three databases; enrichment analysis showed that BP mainly involved neutrophil degranulation, and neutrophil activation involved in immune response; in CC, membrane raft and membrane microdomain were involved; and MF was mainly related to collagen binding and endopeptidase activity. The pathway enrichment showed fluid shear stress and AS, lipid and AS, and TNF signaling pathway (Figure 5). Subsequent construction of PPI networks for potential therapeutic targets showed that VEGFA, IL-1B, IL-6, TP53, and TNF were the core genes with intersecting genes in two databases, while MMP9, SELE, HMOX1, DPP4, and CTSB were core target genes in three datasets (Figure 6).

Molecular docking

Results of PPI network analysis showed that six targets with the highest degree of TNF, TP53, IL-6, IL-1B, VEGFA, and MMP9 were identified, and the corresponding active ingredients were identified by correlated molecular docking (Figure 7).
Network pharmacology and bioinformatics to identify bioactive compounds

Figure 5. Enrichment analysis of three databases shows SL therapeutic targets. (A) Venn diagram of three databases and disease targets. (B) GO enrichment analysis [top 10 results for biological process (BP), cellular component (CC), and molecular function (MF) enrichment analysis]. (C) KEGG enrichment analysis of therapeutic targets (top 10 results).

Figure 6. Protein–protein interaction (PPI) network of SL treatment AS. (A) PPI network analysis of at least two database intersection targets. (B) PPI network analysis of three database intersection targets.
Identification of core active ingredients and their mechanisms of action

We intersected the identified active ingredients of SL with the disease targets of AS and found that they have at least one and a maximum of 40 target genes (Figure 8).

Finally, we identified ursolic acid as the main core ingredient of SL, and 40 targets of ursolic acid overlapped with the potential therapeutic targets of SL for AS. Further, PPI network and enrichment analyses showed that ursolic acid had a high overlapping with the core target genes of SL, GO, and KEGG (Figure 9, Table S1).

Figure 7. Results of the docking of core targets of PPI network with their corresponding active ingredient molecules. (A and B) p53 with 3,4,5-trihydroxybenzoic acid (gallic acid) and ursolic acid docking results. (C–E) Tumor necrosis factor (TNF) with hydroquinone, myricetin, and ursolic acid docking results. (F and G) Docking results of IL-6 with myricetin and ursolic acid. (H and I) Docking results of IL-1B with myricetin and ursolic acid. (J) Docking results of VEGFA with ursolic acid. (K) Docking results of MMP9 with ursolic acid.
Network pharmacology and bioinformatics to identify bioactive compounds

Figure 8. Intersection of active ingredients of SL with AS therapeutic targets. (A) MOL000263. (B) MOL000357. (C) MOL000358. (D) MOL000359. (E) MOL000511. (F) MOL000513. (G) MOL000579. (H) MOL002008. (I) MOL002075. (J) MOL002930. (K) MOL006086. (L) MOL006089.

Figure 9. Bioinformatics analysis of potential therapeutic targets of ursolic acid. (A) Protein–protein interaction (PPI) network of therapeutic targets. (B) Venn diagram of potential therapeutic targets of ursolic acid and therapeutic targets of Kuntai Capsule (KTC). (C) Gene ontology (GO) enrichment analysis of therapeutic targets [top 10 results for biological process (BP), cellular component (CC), and molecular function (MF) enrichment analysis]. (D) Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of therapeutic targets (top 10 results).
Discussion

The pathogenesis of AS is more diverse, with lipid deposition in the circulation, the generation of reactive oxygen species (ROS) causes damage to vascular endothelial function, inducing monocyte migration foam, inflammatory mediator release, and intimal fibrous proliferation, leading to atheromatous plaques (Hafiane, 2019). The complex and variable nature of the AS process poses a great challenge for treatment, and although statins are the main measure for treating AS, because of their single target of action, long-term use can bring serious adverse effects (Varatharajalu et al., 2016). Recent studies have shown that SL has a preventive and curative effect on cardiovascular disease and has the advantage of low toxic adverse reactions. In our study, we proposed to construct a component–target–disease network with the help of network pharmacology, and used PPI to construct network targets for SL and AS from a holistic and systemic perspective, further screen the core genes, identify the active ingredients through molecular docking, and subsequently explore their potential mechanisms of action through GO and KEGG enrichment analysis.

The targets of disease and SL were crossed to finally obtain 67 potential therapeutic targets of SL for AS, and five core targets with intersection in three databases; MMP9, SELE, HMOX1, DPP4, and CTSB were further screened. MMP9 plays an important role in the metabolism of extracellular matrix and collagen, and promoted smooth muscle migration to subendothelium to form atheromatous plaques, thereby accelerating the progression of atherosclerotic plaque formation, and is also associated with plaque instability and rupture (Bakhshian et al., 2017; Rossano et al., 2014; Sierra et al., 2018). SELE encodes a protein present in cytokine-stimulated endothelial cells, and the current study showed that SELE had a key role in the development of AS, and targeting SELE would reduce atherosclerotic lesions, adverse cardiac remodeling, and dysfunction (Fereydouni et al., 2020; Tsoref et al., 2018).

Studies have shown that HMOX1 is highly expressed in plaques of AS patients and positively correlates with disease, accompanied by the production of MMPs and macrophage infiltration (Kishimoto et al., 2018; Wu et al., 2022). DPP4 has pleiotropic properties, and DPP4 inhibitors exert anti-AS effects by a variety of mechanisms that inhibit inflammation and oxidative stress, and improve endothelial cell dysfunction, in addition to improving glycemia, which helps to reduce cardiovascular risk in patients with comorbid diabetes (Liu et al., 2020; Love and Liu, 2021). Studies have shown that CTSB is upregulated in AS lesions; it degrades extracellular matrix; increases the fragility of atherosclerotic plaques; and has a crucial role in the pathogenesis of AS (Zhao and Herrington, 2016).

The KEGG results suggest that SL can act simultaneously on multiple signaling pathways associated with AS disease, including lipid, TNF signaling pathway, IL-17 signaling pathway, and AGE-RAGE signaling pathway in diabetic complications. The AGE-RAGE axis in diabetic patients promotes AS, and decreases the glycation end-products. RAGE expression inhibits the progression of AS; this progression may be associated with vascular protection 18290873. The pathogenesis of AS begins with vascular endothelial cell dysfunction accompanied by low-density lipoprotein (LDL) retention, modified LDL promoting endothelial cell activation and vesicular cell formation, and massive accumulation of intracellular and extracellular matrix lipids as the initial manifestation of AS (Allahverdian et al., 2014; Mundi et al., 2018; Stary et al., 1994).

The most common diabetic complication is cardiovascular and cerebrovascular diseases. Many studies have proved that TNF signaling pathway had a critical role in various diabetic complications. TNF apoptosis, as well as inflammation, and TNF cells are major mediators of inflammation and immunity, and are associated with the pathogenesis of several human diseases. TNF mainly includes TNF-β and TNF-α, which are secreted by T lymphocytes and macrophages, respectively. TNF-α can increase endothelial inflammation and AS by mediating the NF-κB pathway and is involved in the development of AS (Chen and Goeddel, 2002; Gao et al., 2016).

IL-17 is mainly produced by Th17 cells and coordinates local tissue inflammation by inducing the release of pro-inflammatory cytokines and mobilization of chemokines by neutrophils from various cell types, including epithelial cells (Veldhoen et al., 2006). IL-17 also has a significant inflammation pathway. So there is study explore its role in AS. The role of IL-17 has been extensively studied in a variety of inflammatory and autoimmune diseases, but its role in the development of AS remains debatable. Induction of IL-17R-deficient mice on a Western-type diet revealed a 46% reduction in aortic roots and plaques whereas in vivo use of IL-17A-blocking antibodies slowed the development of AS (Kumbhani et al., 2015; Liu et al., 2014). In contrast to these studies, increased production of IL-10I and L-17A induced an anti-inflammatory macrophage phenotype, slowed lesion progression, and reduced vascular inflammation while acting as protective cytokines for AS (Schraml et al., 2009). From these we can conclude that these signaling pathways play a critical role in the progression of AS. However, well-defined functioning of these signaling pathways in AS needs further research.
The main active ingredients of SL include myricetin, oleanolic acid, ursolic acid, sitosterol, and beta-sitosterol. Myricetin is a natural flavonoid extracted from berries, grapes, and herbs with antioxidant capacity. Current studies have shown that it can inhibit cholesterol accumulation in foam cells, thereby improving AS, in addition to inhibiting vascular smooth muscle cell proliferation and migration and suppressing of neoplastic endothelial proliferation (Chen et al., 2021; Meng et al., 2019).

Oleanolic acid is a pentacyclic triterpenoid widely found in plants, and recent studies have shown that it mainly exerts antioxidant effects but could be anti-tumor as well (Li et al., 2015; Pollier and Goossens, 2012; Wang et al., 2013). Recent researches have shown that oleanolic acid could prevent the development of AS and protect human umbilical vein endothelial cells (Pan et al., 2018; Zhang et al., 2018).

Ursolic acid is a pentacyclic triterpene carboxylic acid that mainly exerts anti-inflammatory, antioxidant, anti-tumor, and anti-hyperlipidemic effects (Ali et al., 2007; Ikeda et al., 2008; Somova et al., 2003). In a subsequent study, ursolic acid was found to attenuate AS formation through ROS/NF-κB pathway-mediated lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) (Li et al., 2018). Both sitosterol and beta-sitosterol belong to phytosterols, and studies have shown that sitosterol significantly reduces the expression of NLRP3 gene, a key protein of macrophage inflammatory vesicles, and inhibits the activation of apoptotic proteases, thus acting as an anti-inflammatory agent, while beta-sitosterol inhibits the secretion of inflammatory elements by macrophages and suppresses the migration of vascular smooth muscle cells (He et al., 2022; Liao et al., 2018). Subsequent functional and pathway enrichment analysis of these active components further validated the above mechanism of screening target genes with consistency. Taken together, these studies suggest that the main active ingredients of SL exert anti-atherosclerotic effects through antioxidant, anti-inflammatory, and anti-lipidemic effects, acting on different targets through multiple signaling pathways, thus preventing and treating cardiovascular diseases. However, the limitations of this study including shorting the validation experiments, and the some information such as the patients treatment regimens is lacking.

Conclusion

In summary, this study found that SL can exert anti-atherosclerotic effects through 12 major components, including the regulation of TNF and IL-17 signaling pathway, thus providing a theoretical basis for the follow-up study of SL against AS.

Author Contributions

(I) Conception and design: BJ Zhu, GY Nai, WJ Zhou, ZF Ma; (II) Administrative support: TX Pan; (III) Provision of study materials or patients: GM Ling, ZD Huang; (IV) Collection and assembly of data: ZZ Shi, JX Lin; (V) Data analysis and interpretation: BJ Zhu, GY Nai, ZF Ma; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Funding

This research was supported Baise Scientific Research and Technology Development Program "City-School Science and Technology Cooperation" Project (Baise Science and Technology 20170813).

References


Network pharmacology and bioinformatics to identify bioactive compounds on Arteriosclerosis, American Heart Association. Circulation 89: 2462–2478. https://doi.org/10.1161/01.CIR.89.5.2462


# Supplementary

## Table S1. Overlapping genes of drug targets and disease targets.

<table>
<thead>
<tr>
<th>Genes</th>
<th>Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>AR</td>
<td>BCL2</td>
</tr>
<tr>
<td>PPARG</td>
<td>PRKCA</td>
</tr>
<tr>
<td>PTGS2</td>
<td>TGFBI</td>
</tr>
<tr>
<td>PIK3CG</td>
<td>PON1</td>
</tr>
<tr>
<td>DPP4</td>
<td>NR3C2</td>
</tr>
<tr>
<td>PTGS1</td>
<td>PLAU</td>
</tr>
<tr>
<td>AKR1B1</td>
<td>CTSB</td>
</tr>
<tr>
<td>SMAD1</td>
<td>VEGFA</td>
</tr>
<tr>
<td>FYN</td>
<td>CCND1</td>
</tr>
<tr>
<td>RELA</td>
<td>FOS</td>
</tr>
<tr>
<td>STAT3</td>
<td>MMP9</td>
</tr>
<tr>
<td>BAX</td>
<td>TP53</td>
</tr>
<tr>
<td>CASP9</td>
<td>MAPK8</td>
</tr>
<tr>
<td>MMP2</td>
<td>NFKBIA</td>
</tr>
<tr>
<td>TNF</td>
<td>MMP1</td>
</tr>
<tr>
<td>JUN</td>
<td>MMP3</td>
</tr>
<tr>
<td>IL6</td>
<td>FGFR2</td>
</tr>
<tr>
<td>CASP3</td>
<td>MMP10</td>
</tr>
<tr>
<td>XDH</td>
<td>CREB1</td>
</tr>
<tr>
<td>IL1B</td>
<td>SELE</td>
</tr>
<tr>
<td>CD36</td>
<td>PTGER3</td>
</tr>
<tr>
<td>CYP19A1</td>
<td>MCL1</td>
</tr>
<tr>
<td>PARP1</td>
<td>ATF2</td>
</tr>
<tr>
<td>PROC</td>
<td>CSF2</td>
</tr>
<tr>
<td>CHRM3</td>
<td>PECAM1</td>
</tr>
<tr>
<td>HMOX1</td>
<td>PTPN6</td>
</tr>
<tr>
<td>ICAM1</td>
<td>NOS3</td>
</tr>
<tr>
<td>NQO1</td>
<td>PTPN1</td>
</tr>
<tr>
<td>MAOA</td>
<td>FASLG</td>
</tr>
<tr>
<td>LYZ</td>
<td>CASP1</td>
</tr>
<tr>
<td>GAS6</td>
<td>ENPP7</td>
</tr>
<tr>
<td>RXRA</td>
<td>ADRA2A</td>
</tr>
<tr>
<td>ADRB2</td>
<td>ADRA2B</td>
</tr>
<tr>
<td>SLC6A4</td>
<td></td>
</tr>
</tbody>
</table>